Revolution Medicines (RVMD) is back in focus after regulators in Europe and the U.S. moved daraxonrasib into accelerated review for pancreatic cancer, alongside early trial results for partner drug zoldonrasib in RAS G12D metastatic disease.
See our latest analysis for Revolution Medicines.
After this regulatory and clinical progress, Revolution Medicines’ recent 30 day share price return of 27.63% and year to date share price return of 141.03% suggest strong momentum, while the 1 year total shareholder return is very large.
If breakthroughs in oncology are on your radar, it could be a good moment to broaden your search and check out 40 healthcare AI stocks
The sharp re-rating in Revolution Medicines after its pancreatic cancer updates could be read as a reset around the science, or as investors crowding into the latest oncology story. How does that translate into today’s valuation?
Most Popular Narrative: 42.5% Overvalued
The most followed narrative values Revolution Medicines at $133.70, well below the last close of $190.46, which sets a high bar for the current price.
The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.
Big expectations are built into this story. Forecast revenue ramp, margin shift and a steep earnings multiple all sit underneath that fair value. It is worth understanding which assumptions matter most.
Result: Fair Value of $133.70 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Revolution Medicines story could shift quickly if high cash use persists without revenue, or if key RAS(ON) trials stumble and weaken confidence in the pipeline.
Find out about the key risks to this Revolution Medicines narrative.
Another View: SWS DCF Model Points To Upside
The analyst narrative for Revolution Medicines leans cautious at a fair value of $133.70, yet the Simply Wall St DCF model points in the opposite direction. On this approach, RVMD at $190.46 trades at a large discount to an estimated future cash flow value of $694.73, which frames the current price as a very different story. Which set of assumptions do you find more realistic?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals around Revolution Medicines leave you undecided, it makes sense to move quickly, review the data in detail, and weigh both sides for yourself. To see both the potential upsides and the concerns in one place, start with these 2 key rewards and 3 important warning signs: 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Revolution Medicines?
If Revolution Medicines has sharpened your focus on high conviction opportunities, do not stop here. Use the Simply Wall St screener to uncover other compelling stocks today.
- Target potential mispriced opportunities by scanning a curated set of 45 high quality undervalued stocks that combine quality fundamentals with appealing price tags.
- Prioritize stability by reviewing 74 resilient stocks with low risk scores that score well on resilience, so short term swings are less likely to derail your plan.
- Get ahead of the crowd by searching a screener containing 18 high quality undiscovered gems before attention and liquidity catch up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com